Novel Indole–Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction
Journal of Medicinal Chemistry · 13.04.2023 · 66 (7) · 4868-4887
DOI: 10.1021/acs.jmedchem.2c02036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.03.2023. Verfasst von Zhikun Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Regional Resource Exploitation and Medicinal Research, Huaiyin Institute of Technology, Huai'an 223003, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Prodrugs, Chalcones, Lung Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Huaiyin Institute of Technology, Jiangsu Key Laboratory of Regional Resource Exploitation and Medicinal Research, National Natural Science Foundation of China.
Abstract (Originalsprache)
Developing multifunctional platinum(IV) prodrugs via integrating bioactive pharmacophores into one entity is an attractive strategy to ameliorate the defects of platinum(II) drugs. Herein, a series of indole-chalcone derivative-ligated platinum(IV) complexes were synthesized and evaluated for their anticancer activities. Among them, optimal complex 17a exerted superior activity compared to that of cisplatin (CDDP) against the tested cells but showed lower cytotoxicity toward human normal lung cells. Detailed mechanisms demonstrated that 17a significantly enhanced intracellular accumulation, induced DNA damage, and inhibited migration in A549/CDDP cells. Furthermore, 17a efficiently disturbed the tubulin-microtubule system, initiated reactive oxygen species (ROS)-mediated endoplasmic reticulum stress, and activated a mitochondrion-dependent apoptosis signaling pathway. Besides, 17a was superior to free drugs or their combination in inhibiting cancer growth in A549/CDDP xenografts without inducing obvious side effects. The physical mixture of 16a and CDDP was almost identical to 17a but showed apparent systematic side effects. In summary, our studies may provide an efficient treatment regimen for CDDP resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Regional Resource Exploitation and Medicinal Research, Huaiyin Institute of Technology, Huai'an 223003, China.
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal Uni…
- Guangxi Key Laboratory for Pharmaceutical Molecular Discovery and Druggability Optimization, School of Pharmacy, Guilin Medical University, Guilin 541199, China.
- Traditional Chinese Medicine Department, Huai'an Maternal and Child Health-Care Center, Huai'an 2230003, China.
ORCID-Profile: Hengshan Wang
Förderung
- Huaiyin Institute of Technology
- Jiangsu Key Laboratory of Regional Resource Exploitation and Medicinal Research
- National Natural Science Foundation of China
- Natural Science Foundation of the Jiangsu Higher Education Institutions of China
Zitieren
APA
Liu, Z., Wang, M., Huang, R., Hu, T., Jing, Y., Huang, X., Hu, W., Cao, G., & Wang, H. (2023). Novel Indole–Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction. Journal of Medicinal Chemistry, 66(7), 4868-4887. https://doi.org/10.1021/acs.jmedchem.2c02036
Vancouver
Liu Z, Wang M, Huang R, Hu T, Jing Y, Huang X, et al. Novel Indole–Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction. Journal of Medicinal Chemistry. 2023;66(7):4868-4887. doi:10.1021/acs.jmedchem.2c02036
BibTeX
@article{Liu2023,
author = {Liu, Zhikun and Wang, Meng and Huang, Rizhen and Hu, Tianhui and Jing, Yi and Huang, Xiaochao and Hu, Weiwei and Cao, Guoxiu and Wang, Hengshan},
title = {Novel Indole–Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {7},
pages = {4868--4887},
doi = {10.1021/acs.jmedchem.2c02036}
}
EUVIMED